Action TEVJF TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Teva Pharmaceutical Industries Limited Other OTC

Actions

TEVJF

IL0006290147

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Les nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiques
BU
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
BU
Teva Announces Launch of Authorized Generic of Victoza, in the United States
AQ
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
BU
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
BU
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna
AQ
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
BU
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
BU
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.
AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
BU
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
AQ
New EVP, Teva Global Operations appointed
AQ
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
AQ
Teva Pharmaceutical Industries : Immediate Report
PU
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
BU
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
AQ
Teva to Present at the 2024 Bank of America Healthcare Conference
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TEVA
  4. Action TEVJF
  5. Actualités Teva Pharmaceutical Industries Limited
  6. Communiqués